



107 College Road East
Princeton, NJ 08540
Tel: 609.608.1246
jcalvarez@drreddys.com

VIA EMAIL – AGO.highcostprescriptiondrugs@vermont.gov

March 2, 2020

Vermont Attorney General’s Office
109 State Street
Montpelier, VT 05609

RE: New Prescription Drug – 30-Day Notice

Dear Sir or Madam,

Dr. Reddy’s Laboratories, Inc. (“Dr. Reddy’s”) is providing this information in accordance with 18 V.S.A. § 4637(c), which requires that prescription drug manufacturers notify the Office of the Attorney General and to provide certain information following the release of a drug in the commercial market whose Wholesale Acquisition Cost (“WAC”) exceeds the threshold set for a specialty drug under the Medicare Part D Program.

NDC:	43598-0459-01
Product Description:	Trientine Hydrochloride Capsules, USP 250mg
Date of Introduction to Market:	02/06/2020
WAC:	\$5000 per 100 pill count bottle
Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	This is a generic equivalent of an existing innovator product. However, the storage condition for this product is different than the innovator brand, as a result, Dr. Reddy's may have to educate the physicians, patient groups and other stakeholders like purchasing agents, buyers and pharmacist of this difference in product handling. For this purpose, we may provide them with product sell sheets which include product name, product description, available pack information, and order entry details in the form of mailers or emails. The spend on any such materials will be less than \$5,000 per year.
The estimated volume of patients that may be prescribed the drug	Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis. Specifically, Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its Trientine HCL Capsules given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; and (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient.
Was the drug granted breakthrough therapy designation by the federal Food and Drug Administration (FDA) prior to final approval?	No
Did the drug receive a priority review by the federal Food and Drug Administration prior to final approval?	No

The date and price of acquisition if the drug was not developed by the manufacturer	N/A
---	-----

Please do not hesitate to contact us if you have any questions.

Regards,



Juan Alvarez
Government Contracts & Pricing
Dr. Reddy's Laboratories, Inc.